Advanced Prostate Cancer Patients May Respond Well to Keytruda Immunotherapy, According to Study

Advanced Prostate Cancer Patients May Respond Well to Keytruda Immunotherapy, According to Study
Immunotherapy with Keytruda (pembrolizumab) may be an effective way to treat advanced-stage prostate cancer, according to a preliminary study conducted by researchers at Oregon Health and Science University (OSHU) Knight Cancer Institute. “It’s pretty remarkable, especially in light of the fact that many people doubted this approach could work at all,” said Dr. Julie Graff in a press release. Graff is the senior author of the study "Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer," published in the journal Oncotarget. Keytruda is a monoclonal antibody that blocks the PD-1 receptor on the surface of  immune T-cells, allowing them to recognize and destroy tumor cells. The FDA-approved drug has been shown to work well in melanoma and lung cancer but had so far not produced any evidence of anti-tumor activity in prostate cancer. Researchers administered Keytruda in 10 men with metastatic prostate cancer who had received androgen deprivation therapy or the androgen receptor antagonist Xtandi (enzalutamide) but failed to respond to it. Three of the 10 men who participated to the trial responded remarkably we
Subscribe or to access all post and page content.